Compare Duke Energy Corp (DUK) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Gilead Sciences, Inc. — how do they compare? Duke Energy Corp trades at $116.89 (market cap $91.10B), while Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 2× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Gilead Sciences, Inc. for 111 Days on average.
| DUK | GILD | |
|---|---|---|
Market Cap | $91.10B | $182.40B |
Volume | 4,199,050 | 4,469,821 |
Sector | Utilities | Health |
52-Week High | $133.46 | $155.80 |
52-Week Low | $113.23 | $116.74 |
Typical Hold Time | 74 Days | 111 Days |
Enterprise Value | $183.61B | $205.46B |
Dividend Yield | 3.71% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.
DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
